AICU Inc

What AICU Inc does

AICU Inc (주식회사 에이아이씨유) is a South Korea-based medical AI company founded in October 2023 and headquartered in Daegu that develops vision AI solutions for non-invasive chronic disease screening and full-cycle care. Its portfolio comprises three core products: the Fecal Scanner (smartphone-based gut health monitoring with 93.2% clinical accuracy validated against colonoscopy and AUROC ≥0.849, including Bristol Stool Scale auto-classification and microhemorrhage detection), the Gait Scanner (marker-less camera-based brain health assessment analyzing 20+ gait parameters in 3-5 seconds for early screening of Normal Pressure Hydrocephalus, Parkinson's disease, and fall risk, deployable on kiosk or mobile), and the AI iNPH Diagnosis Support System (automated brain MRI quantification with Evans Index, Callosal Angle, DESH detection, and explainable AI-driven differential diagnosis between iNPH and Alzheimer's, integrated with PACS and EMR). The technical foundation rests on a proprietary clinical dataset drawn from partnerships with six university hospitals and 30+ SCI publications plus 30+ domestic and international (US, Japan) patents.

The company monetizes via subscription/recurring revenue across three vertical segments: Medical & Healthcare (university hospitals, checkup centers, nursing hospitals for degenerative brain disease screening, rehabilitation monitoring, and IBD home care), Industrial Safety (construction, heavy industry, and logistics sites for rapid worker health screening and serious-accident prevention), and Public & Insurance (public health centers, municipal dementia care centers, and insurance companies for community dementia prevention). Distribution combines direct enterprise field sales for institutional buyers, kiosk deployment in medical and public spaces, and consumer mobile apps for individual users. AICU is led by CEO 황은아 (Hwang Eun-ah), whose background includes CFO and AI project roles, and CTO 정성문 (Jeong Seong-mun), a Kyungpook National University medical school professor, Director of the KNU Hospital Medical AI Research Center, former JAIST assistant professor, and recipient of the Minister of Science and ICT Award, supported by a clinical advisory board of professors across neurovascular surgery, gastroenterology, and neurology.

Name

AICU Inc

Legal name

주식회사 에이아이씨유 (AICU Inc.)

Website

https://www.aicu.life/

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

AICU Inc is a Daegu-based medical AI company that builds vision AI tools for non-invasive chronic disease screening, including smartphone-based fecal analysis, marker-less gait brain health monitoring, and MRI-based iNPH differential diagnosis, serving healthcare institutions, industrial safety operators, and public/insurance organizations in South Korea.

Ownership category

akta.pro rank

Product category

AI Healthcare Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical and Diagnostic Laboratories (62151)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Responsible AI, Security & Privacy Platforms (Safety, Guardrails, PII) (HDAEANAG)

Keywords

• AI healthcare software
• Vision AI diagnostics
• Gait analysis platform
• Medical imaging AI
• Digital health screening

Headquarters

HQ city

Daegu

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. AI Healthcare Solutions: Vision AI-based chronic disease monitoring solutions for full-cycle care from disease prevention to treatment, including Fecal Scanner and Gait Scanner products.
2. Fecal Scanner: Non-invasive colorectal health monitoring via smartphone photo capture with clinical accuracy of 93.2% and personalized lifestyle guidance.
3. Gait Scanner: Brain function monitoring through gait pattern analysis in 3-5 seconds, providing 20+ gait parameters for early prediction of brain diseases.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

AICU Inc develops and sells vision AI-powered chronic disease monitoring software for full-lifecycle care from disease prevention to treatment. Core offerings include the Fecal Scanner (smartphone-based non-invasive gut health monitoring with 93.2% clinical accuracy vs colonoscopy) and the Gait Scanner (marker-less 3-5 second walking analysis quantifying 20+ gait parameters for brain disease screening), plus the AI iNPH Diagnosis Support System for brain MRI analysis and differential diagnosis. All products leverage medical big data from 6 university hospital partnerships combined with deep learning vision AI.

Product overview

AICU Inc provides a portfolio of vision AI-powered healthcare solutions for full-lifecycle disease prevention and treatment. The core offerings include Fecal Scanner (AI gut health monitoring via smartphone), Gait Scanner (brain function monitoring via gait pattern analysis), and AI iNPH Diagnosis Support System (brain MRI analysis for iNPH/AD differential diagnosis). All products leverage medical big data from 6 university hospitals combined with deep learning vision AI technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Fecal Scanner AI-powered smartphone-based gut health monitoring solution that enables non-invasive stool analysis with 93.2% clinical accuracy compared to colonoscopy. Detects microscopic bleeding, classifies stool using the Bristol Stool Scale, and provides personalized lifestyle guidance by integrating meal, symptom, and bowel movement records. Designed for individual consumers via mobile app and for healthcare institutions for at-home IBD patient management.
• Gait Scanner Vision AI-based gait pattern analysis solution that monitors brain health through 3-5 second walking analysis using marker-less camera tracking. Quantifies 20+ gait parameters (stride, speed, balance) for early screening of Normal Pressure Hydrocephalus (iNPH), Parkinson's disease, and fall risk. Available on kiosk and mobile platforms for healthcare institutions, public spaces, and individual consumers.
• AI iNPH Diagnosis Support System AI-powered brain MRI analysis solution for automated quantification of brain structures and differential diagnosis between Idiopathic Normal Pressure Hydrocephalus (iNPH), Alzheimer's Disease (AD), and healthy controls. Features automated volumetric measurement (Evan's Index, Callosal Angle, DESH sign), explainable AI with confidence scores, and one-click PACS/EMR report generation. Designed for hospital radiology departments and university hospitals.

Quantifiable outcome

• 93.2% clinical accuracy for fecal scanner vs colonoscopy results
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability9 records

Feature9 records

Partnerships

One partnership is on record.

• Kyungpook National University Hospital (경북대학교병원)coreStrategic or Co-development PartnerClinical data partnership from 6 university hospitals for AI training; Medical AI Research Center led by CTO 정성문 at KNU Hospital; Clinical Advisory Board including professors 박재찬 (Neurovascular Surgery), 김은수 (Gastroenterology), and 강경훈 (Neurology)

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lunit: Korean medical imaging AI company offering AI-powered radiology and pathology solutions for cancer screening and diagnostics. Directly comparable to AICU as a Korea-based medical imaging AI peer with FDA-cleared products and academic hospital validation.
• Viz.ai: US AI medical imaging company specializing in AI-powered stroke detection and workflow coordination. Comparable as a specialist medical imaging AI peer with explainable outputs and deep clinical integration.
• Arterys: AI medical imaging company offering cloud-native, FDA-cleared deep learning workflows for cardiac, lung, and liver MRI/CT analysis. Comparable as a vision-AI peer focused on MRI quantification and clinical reporting.
• Qure.ai: India-based AI company building deep learning models for radiology interpretation across chest, head, and musculoskeletal imaging. Comparable as an emerging vision-AI radiology peer with multi-region validation and clinical evidence focus.
• Aidoc: Israeli AI radiology company offering FDA-cleared AI workflows for CT and MRI triage across multiple pathologies. Comparable as a vision AI peer focused on medical imaging with PACS integration and enterprise hospital sales.
• VUNO: Korean medical AI company developing deep learning-based diagnostic support solutions for chest X-ray, CT, and EEG. Comparable as a domestic Korean competitor applying vision AI to clinical imaging workflows with hospital sales motion.

Broad incumbents

• Mindray: Major Chinese medical device manufacturer with a growing AI-enabled patient monitoring and diagnostic imaging portfolio. Comparable as a broad incumbent in medical devices with adjacent AI diagnostic capabilities and global distribution.
• Nanox (formerly Zebra Medical Vision): AI imaging company developing AI-based analytics for radiology, integrated with the Nanox imaging system. Comparable as a broad medical imaging AI incumbent combining hardware and AI software.
• DeepHealth (RadNet): Subsidiary of RadNet applying AI to medical imaging across breast, lung, and prostate screening at scale. Comparable as a broader imaging-AI incumbent with significantly more capital and distribution reach than AICU.

Emerging players

• Ibex Medical Analytics: Israel-based AI company focused on cancer diagnostics in pathology, with expanding digital diagnostic AI tools. Comparable as an emerging AI diagnostics peer pursuing clinical-grade accuracy and pathology/radiology workflow integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aicu-life

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AICU Inc